Publications

Links | 2021 | 2020 | 2019 | 2017 | Selected Publications
 

Links

Unisciences: www.unil.ch/unisciences/lilianetenenbaum

ORCID (Open Researcher and Contributor ID):ID 0000-0003-4619-9660

 

TOP ^

2021

Duarte Azevedo, M., Sander, S., Jeanneret, C., Olfat, S., Tenenbaum, L. (2021). Selective targeting of striatal parvalbumin-expressing interneurons for transgene delivery. J. Neurosci. Methods. 354: 109105. doi: 10.1016/j.jneumeth.2021.109105.

 

Tenenbaum, L. (2021). CDNF: an innovative actor in disease-modifying approaches for Parkinson’s disease. Commentary. Mol. Ther. 29 (9): 2634-2636. doi: 10.1016/j.ymthe.2021.08.015.

TOP ^

2020

Bachoud-Lévi, A.-C., on behalf of the multicentric Intracerebral Grafting in Huntington’s Disease Group (2020). Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II Trial. Mov Disord. 35(8):1323-1335.

Duarte Azevedo, M., Sander, S., Tenenbaum, L. (2020). GDNF, A Neuron-Derived Factor Upregulated in Glial Cells during Disease. J Clin Med. 9(2):456 doi: 10.3390/jcm9020456.

TOP ^

2019

Lasbleiz, C., Mestre-Frances, N., Devau, G., Luquin, R., Tenenbaum, L., Kremer, E.J. , Verdier, J.-M. (2019). Combining gene transfer and nonhuman primates to better understand and treat Parkinson’s disease. Front. Mol. Neurosci. 12:10. doi: 10.3389/fnmol.2019.00010.

 

Dwir, D., Giangreco, B., Xin, L., Tenenbaum, L., Cabungcal, J.-H., Steullet, P., Goupil, A. , Cleusix, M., Jenni, R., Baumann, P. , Klauser, P. , Conus, P., Tirouvanziam, R.,  Cuenod, M,  Do, K.Q. (2019). MMP9 / RAGE pathway overactivation mediates redox dysregulation and neuroinflammation, leading to inhibitory / excitatory imbalance: a reverse translation study in schizophrenia patients. Mol. Psychiat. 25(11):2889-2904. doi: 10.1038/s41380-019-0393-5.

TOP ^

2017

Tenenbaum, L. and Humbert-Claude, M. (2017). Glial cell line-Derived Neurotrophic Factor gene delivery in Parkinson’s disease: a delicate balance between neuroprotection, trophic effects and unwanted compensatory mechanisms. Front. Neuroanat. 11: 29. doi: 10.3389/fnana.2017.00029

Liu, S., Sandner, B., Schackel, T., Nicholson, L., Chtarto, A., Tenenbaum, L., Puttagunta, R., Müller, R., Weidner, R., Blesch, A. (2017). Regulated Viral BDNF Delivery in Combination with Schwann Cells Promotes Axonal Regeneration through Capillary Alginate Hydrogels after Spinal Cord Injury. Acta Biomater. 60: 167-180

TOP ^

Selected Publications

Tenenbaum, L., Jurysta, F., Stathopoulos, A., Puschban, Z., Melas, C., Hermens, W.T.J.M.C., Verhaagen, J., Pichon, B., Velu, T.,  and Levivier, M. (2000). Tropism of AAV-2 vectors for neurons of the globus pallidus. NeuroReport 11: 2277-2283.

Chtarto, A., Bender, H.U., Hanemann, C.O., Kemp, T., Lehtonen, E., Levivier,M., Brotchi, J., Velu, T. and Tenenbaum, L. (2003). Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther. 10: 86-96.

Tenenbaum, L., Peschanski, M., Melas, C.,  Rodesh, F., Lehtonen, E., Stathopoulos, A., Chtarto, A., Velu,T., Brotchi, J. and Levivier, M. (2004). Efficient early and sustained transduction of human fetal mesencephalon using AAV2 vectors. Cell Transplant 13: 565-571.

Chtarto, A., Yang, X., Bockstael, O., Melas, C., Blum, D., Jaspar, J.-M., Levivier, M., Brotchi, J., Velu, T., and Tenenbaum, L. (2007). Controlled delivery of glial cell line-derived neurotrophic factor by a tetracycline-inducible AAV vector. Exp. Neurol. 204(1): 387-399.

 

Lubansu, A., Abeloos, L., Blum, D., Brotchi, J., Levivier, M., Tenenbaum, L. (2008). Recombinant AAV viral vectors serotype 1, 2 and 5 mediate differential gene transfer efficiency in rat striatal fetal grafts. Cell Transplant. 16(10):1013-20.

 

Bockstael, O., Chtarto, A., Wakkinnen, J., Yang, X., Melas, C., Levivier, M., Brotchi, J., Tenenbaum, L. (2008). Differential transgene expression profiles of cross-packaged AAV2/1 vectors using the tetracycline-inducible and CMV promoters in the rat brain. Hum. Gene Ther. 19(11): 1293-1306.

 

Dismuke, D. J., Tenenbaum, L. , and Samulski, R. J. (2013). Biosafety of Recombinant Adeno-associated Virus Vectors. Curr. Gene Ther. 13: 434-452.   

 

Ayuso, E., Blouin, V., Lock, M., McGorray, S., Alvira, M.R., Auricchio, A.,  Bosch, F,. Bucher, S., Chtarto, A.,  Clark, K.R., Darmon, C., Doria, M., Fountain, W., Gao, G., Giacca, M., Kleinschmidt, J., Leon, X., Leuchs, B., Mizukami, H., Normand, Y., Ozawa, K., Surosky, R., Tenenbaum, L., Van Linden, I., Weins, B., Wright, J.F., Zelenaia, O., Zentilin, L., Snyder,  R.O. and Moullier, P. (2014). Manufacturing and Characterization of a Recombinant Adeno-Associated Virus Type 8 Reference Standard Material. Hum. Gene Ther. 25: 977-987.

 

Humbert-Claude, M., Duc, D., Dwir, D., Thieren, L., Sandström von Tobel, J., Begka. C., Legueux, F., Velin, D., Maillard, M.H., Do. K.Q., Monnet-Tschudi, F., Tenenbaum, L. (2016). Tollip, an early regulator of the acute inflammatory response in the substantia nigra. J. Neuroinflamm. 13(1):303.

Chtarto A,  Humbert-Claude M and Bockstael O, Das AT, Boutry S, Breger L, Barroso-Chinea P, Klaver B, Melas C, González-Hernández T, Müller R, DeWitte O, Levivier M, Lundberg C, Berkhout B, Tenenbaum L. (2016). A  regulatable AAV vector mediating GDNF biological effects at clinically-approved sub-antimicrobial doxycycline doses.  Mol. Ther. Meth. Clin. Dev. 5: 16027

TOP ^

CHUV - Pavillon 3 - Avenue de Beaumont - CH-1011 Lausanne
Switzerland
Tel. +41 21 314 21 20
Fax +41 21 314 08 24
Centre Hospitalier Universitaire Vaudois (CHUV) Université de Lausanne